BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

AACR data propel Syndax shares Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose $7.99 (69%) to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613 that showed responses in two out of...
BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

Chinese team provides data for Gilead’s remdesivir against 2019-nCoV A group from the Chinese Academy of Science’s Wuhan Institute of Virology and the Beijing Institute of Pharmacology and Toxicology showed that remdesivir reduced 2019-nCoV infection...
BioCentury | Jan 17, 2020
Translation in Brief

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas. The premise of synthetic lethality is...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer...
BioCentury | Jun 4, 2019
Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified gemcitabine, Jevtana cabazitaxel and Jakavi ruxolitinib as drugs that could help treat pediatric AML. High throughput screening of a library of...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting MLL5 could help treat RNA viral infections. In primary mouse macrophages infected with vesicular stomatitis virus (VSV) or Sendai virus, knockout of MLL5 decreased levels...
BioCentury | Apr 10, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy HSPCs derived from iPS cells and engineered to express the MLL-AF4 fusion oncogene could improve the engraftment of HSPC transplant therapies. The HSPCs were generated by inducing differentiation of iPS cells from...
Items per page:
1 - 10 of 96